Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 4 Results

Title
Intervention Indication Therapeutic Area Year Actions
Bintrafusp alfa for locally advanced or metastatic biliary tract cancer – second-line Bintrafusp alfa (M7824; GSK4045154) Biliary tract cancer Gastrointestinal Cancer 2020 View  |  Download
Durvalumab in addition to gemcitabine and cisplatin for advanced biliary tract cancer – first line Cisplatin (Platinol) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Gemcitabine (Gemzar; gemcitabine hydrochloride) Biliary tract cancer Gastrointestinal Cancer 2021 View  |  Download
Pembrolizumab in combination with gemcitabine and cisplatin for previously untreated advanced/unresectable biliary tract cancer Cisplatin (Platinol) , Gemcitabine (Gemzar; gemcitabine hydrochloride) , Pembrolizumab (Keytruda; MK-3475) Biliary tract cancer Gastrointestinal Cancer 2021 View  |  Download
Zanidatamab for treating advanced or metastatic HER2-positive biliary tract cancer in adults Zanidatamab (ZW-25) Biliary tract cancer Gastrointestinal Cancer 2023 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications